Vascular endothelial growth factor, p53, and the H-ras oncogene in Egyptian patients with bladder cancer

Table 1 Sequence of oligonucleotide primers

Primer	Sequence (5'→3')
Outer primers
Sense (A)	AGGAGCGATGACGGAATATAAGC
Antisense (B)	GGCTCACCTCTATAGTGGGGTCGTATT
Inner primers
Sense (C)	AATATAAGCTGGTGGTGGTGGGCGC
Antisense (D)	GGGGTCGTATTCGTCCACAAAATG

Table 2 Clinicopathological characteristics of the transitional cell carcinoma group and their relation to p53 immunostaining n (%)

Variable	n	P53		P value
		Positive	Negative
Age (yr)
≤ 50	11 (22)	7 (14)	4 (8)	0.851
> 50	39 (78)	26 (52)	13 (26)
Sex
Male	42 (84)	27 (54)	15 (30)	0.558
Female	8 (16)	6 (12)	2 (4)
Grade
G2	18 (36)	8 (16)	10 (20)	0.016
G3	32 (64)	25 (50)	7 (14)
Stage
pT1	8 (16)	3 (6)	5 (10)	0.079
pT2	28 (56)	21 (42)	7 (14)
pT3	7 (14)	6 (12)	1 (2)
pT4	7 (14)	3 (6)	4 (8)
Node status
Positive	6 (12)	2 (4)	4 (8)	0.072
Negative	44 (88)	31 (62)	13 (26)

Table 3 Clinicopathological characteristics of the transitional cell carcinoma group and their relation to VEGF immunostaining n (%)

Variable	n	VEGF		P value
		Positive	Negative
Age (yr)
≤ 50	11 (22)	5 (10)	6 (12)	0.364
> 50	39 (78)	12 (24)	27 (54)
Sex
Male	42 (84)	16 (32)	26 (52)	0.161
Female	8 (16)	1 (2)	7 (14)
Grade
G2	18 (36)	6 (12)	12 (24)	0.941
G3	32 (64)	11 (22)	21 (42)
Stage
pT1	8 (16)	3 (6)	5 (10)	0.935
pT2	28 (56)	9 (18)	19 (38)
pT3	7 (14)	3 (6)	4 (8)
pT4	7 (14)	2 (4)	5 (10)
Node status
Positive	6 (12)	1 (2)	5 (10)	0.339
Negative	44 (88)	16 (32)	28 (56)

VEGF: Vascular endothelial growth factor.

Table 4 Clinicopathological characteristics of the transitional cell carcinoma group and their relation to H-ras mutations n (%)

Variable	n	H-ras mutation		P value
		Positive	Negative
Age (yr)
≤ 50	11 (22)	1 (2)	10 (20)	0.479
> 50	39 (78)	7 (14)	32 (64)
Sex
Male	42 (84)	7 (14)	35 (70)	0.768
Female	8 (16)	1 (2)	7 (14)
Grade
G2	18 (36)	4 (8)	14 (28)	0.368
G3	32 (64)	4 (8)	28 (56)
Stage
pT1	8 (16)	1 (2)	7 (14)	0.156
pT2	28 (56)	4 (8)	24 (48)
pT3	7 (14)	3 (6)	4 (8)
pT4	7 (14)	0 (0)	7 (14)
Node status
Positive	6 (12)	0 (0)	6 (12)	0.254
Negative	44 (88)	8 (16)	36 (72)

Table 5 Kaplan-Meier estimates of 3-year disease-free survival in relation to patient and tumour characteristics in the transitional cell carcinoma group

Characteristic	n	3-year survival rate (%)	P value
Total No.	50	68.0
Age (yr)
≤ 50	11	71.8	0.487
> 50	39	54.5
Sex
Male	42	64.3	0.126
Female	8	87.5
Grade
G2	18	72.2	0.128
G3	32	65.6
Stage
pT1	8	100	0.601
pT2	28	71.4
pT3	7	57.1
pT4	7	28.6
Node status
Positive	6	16.7	0.008
Negative	44	75.0
p53
Positive	33	63.6	0.962
Negative	17	76.5
VEGF
Positive	17	64.7	0.791
Negative	33	69.7
H-ras
Positive	8	66.7	0.967
Negative	42	75.0